{"name":"Cortexyme Inc.","slug":"cortexyme-inc","ticker":"","exchange":"","domain":"","description":"Cortexyme Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat and prevent Alzheimer's disease and other neurodegenerative conditions. The company's lead candidate, COR388, is in Phase 2 trials, while COR588 is in Phase 1.","hq":"","founded":0,"employees":"~100","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.2B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":18590000,"netIncome":-56828000,"cash":51214000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"COR388 capsule","genericName":"COR388 capsule","slug":"cor388-capsule","indication":"Alzheimer's disease","status":"phase_2"}]}],"pipeline":[{"name":"COR388 capsule","genericName":"COR388 capsule","slug":"cor388-capsule","phase":"phase_2","mechanism":"Targeting tau protein aggregation","indications":["Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNNFJ0ZjBYYkFkdXNBWFZPT2YwYzFSVy1Zei1US0plS29acGY5YldSblFXVFZwREtiMlRFRmVZTUJMeXF6SXBySWltMExwNlRUUjJDdGdzUFJPc3U2ZWlqeElSeEpFaGtMU09CX1lEbkJPcE1mVmN5YzdNazVQOWJPdG5yUQ?oc=5","date":"2026-02-13","type":"pipeline","source":"pharmaphorum","summary":"Bankruptcy threat looms as Quince runs out of options - pharmaphorum","headline":"Bankruptcy threat looms as Quince runs out of options","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVllmaWxhNVNUSFBLNkM3RE1GRzBVSmplOFpFTnVaRGVDd1JLOUo3MWROTTg2bDVtSFBYLTRfUUV4cG9QMXprV203Vk5laUpFNURXM3hObDByb1k4RzhiQkFiUnlLOWpUSWt4emFKTXZoOTJxZ0JRS19QQ1BnWjJKV1dUS1JXWVdWZGFHYzlmenVRdXdYcklDTFFUVmRqc05vc0tkQUI0RDBBdw?oc=5","date":"2025-10-08","type":"pipeline","source":"The Business Journals","summary":"Peninsula biotech lands big NIH grant to target common mouth bacteria at center of Alzheimer's disease - The Business Journals","headline":"Peninsula biotech lands big NIH grant to target common mouth bacteria at center of Alzheimer's disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxNdTlUVV9UQ0M2bmowemt4UVFrZHlSbzRpMlZ0dnFfNVdOaTEwb1lPNnNiaHFYZFV5TVBJclBuT2dnZU9OeXhqV2Vtc2NabVpSZXY2bXdNblFvR2t2Sl93MGF0bkgxbzJCblZhWUxuckZXdTlxZExlQ2RiRGtHakNpU3dqNG5uaG4yNkUwYVVDM3hxVW1fbDdGdUdSRGxGanl3aHd1cmE2cWJuaUhOSlBtc242M2VnWnpFRm9EdGJLeGJNWk5EbWRWb19yWW9ob2g5T2dFRjNINlNRYm1fTG41dmxIWU9WQkxhUlJpVGZXcjY3enRJR1liTVIzcXZjZFVSTFVVbWp2alhuOXVLc1oyZ1dQajZlRWptMTVOTHdyRE02YWV1RWNNWXV3c1pxWjVmMXRjM3pubmthc0p5ZEVvMkpkOWZaZlB3TlE?oc=5","date":"2025-04-29","type":"trial","source":"GlobeNewswire","summary":"Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Phenylketonuria Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPMW5Cbm9rTXB2Z3FIVEpGcmwzM1dBZ3pQY3Z4aG1oTEJMZVhMWTBwdU5vWDdpdDhDM0VqaXFFd1VFMEtSOU5fSmF0X3VzM09WZEdhQkl3cWVGTDdrRVdjTGhIRU03akRPM29UX3VzTjVMLTFrb0xUZ3cwcWgyU2tnZ0tBTEQzNkl2U3lrR0hGWWd0bkhaSFRPWmhaOFNTYXBuM0Z1ZW1QMlBISnR6WHlNUlFJVUp0T3pMMDdvRHcySFVXVExhd0VvanEyNWZNTF9LdE9ERTZuRUpqVkdfUzhFMkJ4VDQ5OUpvX1Npd1ZyNHpjTnVqZFlNYkE5U1N3MlVXYzBpd2hlNA?oc=5","date":"2025-03-03","type":"pipeline","source":"GlobeNewswire","summary":"LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight - GlobeNewswire","headline":"LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBhOHhad2g2RlQ0U1lCOS1TRVBzazdQb1NOZXB0cVNZWmlOUWZYRnVCUkFZY2RlQm45YTZuektUUmF3VmVRZWRvQWtjVzNkUQ?oc=5","date":"2024-01-04","type":"pipeline","source":"worth.com","summary":"Casey Lynch - worth.com","headline":"Casey Lynch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQcmRoRTBxdzYwcnpMVW9XXzZoSmphUTZUamEyeUgxenZjaWRCSFBoc1BMSFRRaUpPSFBXdWdKRll2LWRGQV9tenV1R3lxek8zem8ybzlaRUxPcFUwM3Q4dFh2cl9vdHJ4Y1JDQS13TWM5SnFfWVRqem9vTVdPWF9Zck13eXUzaS1UZTB3NzlxNlFCdXFsQVRVZWkxRm9WZkotRVJQdHJLcWtqMEJnMzRrWF8zbjRSNllVRjV2OHZUZzFDTHNlTzhBR25RYldSbHQ3aTRsNnl0OHhNQWpHTWFra3ZOZ1NOZnM1aWxNMFhkSmtISkZudkxv?oc=5","date":"2023-01-27","type":"pipeline","source":"Business Wire","summary":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Business Wire","headline":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQd0lGT0c2cldJZ3QzNmhpOEk1MjVHbkYtMlpZTDlwc2UtTEk1ODZCdXcwMEJ1V2NfRUV6ZEs0ZWJOMHF6QnVMRFFFSGxsWEdlaVp6NDRzUFRJMVZ0cHg4aU9ZSUs3RE5IOEY0b1U0b2JsTVhyTXRVaVl3U05xR0dOMUlCTzlGM054cVBxMmRHS0E3cXFpN1Ryak9Pa0p4QXU5c3ZQSnUwNVZvTllEM2hXUkh3?oc=5","date":"2023-01-27","type":"pipeline","source":"The Business Journals","summary":"Casey Lynch and her Cortexyme team regroup at Lighthouse for another shot at Alzheimer's - The Business Journals","headline":"Casey Lynch and her Cortexyme team regroup at Lighthouse for another shot at Alzheimer's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPV0hSTHRZTG5Ta2JyODI4SUE0S0JpY0trNUY1WWtvQ1lnRmMya0ZfNWVTTlpLNXBqNXFlcmM2a0tDLTgtVVVRcURIUTFEQnRQMWNTdFZEeGhQeUhhRTN6ZnpzYXMwVUlCbXp5Zmp5eUQyTTRObzBmODhaM1JZTnZqOTdWSWQwakVzemFYcS1mZ3E3cnRiNVpWUG55aHJtX3l5?oc=5","date":"2022-06-01","type":"pipeline","source":"Business Insider","summary":"Employees at top biotech companies can get paid up to $1.6 million. Here's where workers made the most in 2021. - Business Insider","headline":"Employees at top biotech companies can get paid up to $1.6 million. Here's where workers made the most in 2021.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPSWZ4RjJLNHlrQ0VXRlBwUlJGNWs5bDlsN093ZzVHb3A5cHZDNmpjdjlndFNxUEN0R21MUW9RYTZZMGVWdUlGY1VxS25uM2dBUG5KV0xVak9odWdWa2pvd1RneW1vZTNEQ3BFRHFBMkhSQm9WVThBQTUwemtheDhtZmlfQk1MMXRZRTZvODFB?oc=5","date":"2022-01-26","type":"regulatory","source":"BioPharma Dive","summary":"Cortexyme to shift focus after FDA places hold on experimental Alzheimer’s drug - BioPharma Dive","headline":"Cortexyme to shift focus after FDA places hold on experimental Alzheimer’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPSEJuYlBJVmlPblJ1TG9rREdOWlBlUE0zbVJIQUdMN1g5cUUyOENRWUlFSGI1ZVBhTGszSkJ0QU9vZk4zeFVIM0hnSnJDR3BQVEFvX3Q0YUlDODZuTElLQjh5MjRKb196YW5ISjhsQTZzUWd5UlhaNXAtZHFJSUFxb1NvWGZqWGNPOGxvUVJTTU5jWFAza2RzX05oMkx0TkJnQVlJZ3FndDgxQXI5c215VHhNZFlsQQ?oc=5","date":"2021-10-27","type":"trial","source":"Bloomberg.com","summary":"Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg.com","headline":"Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18590000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-56828000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":51214000,"cashHistory":[],"totalAssets":114478000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}